Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients.
Chronic hepatitis C virus (HCV) infection is quite prevalent in long-term hemodialysis (HD) patients. Patients who are candidates for renal transplantation might be treated, before grafting, with interferon-alpha (IFN-alpha). Among 39 HCV-positive long-term HD patients treated with IFN-alpha, we observed three cases of reversible posterior leukoencephalopathy syndrome (PLES). PLES included headaches in three patients, confusion in three patients, cortical blindness in two patients, visual hallucinations in one patient, seizures in three patients, and respiratory distress in one patient in a context of fluid overload and severe hypertension in all cases. The three patients were receiving IFN-alpha and recombinant erythropoietin therapies simultaneously for de novo anemia. Contrast-enhanced computed tomography scan or magnetic resonance imaging showed low-density areas in the occipital lobes (in three patients), frontal lobes (in one patient), and temporal lobes (in one patient). After withdrawal of IFN-alpha and recombinant erythropoietin therapies, hemodiafiltration, and symptomatic treatment of seizures and hypertension, PLES was reversible within 1 week in one patient, 10 days in one patient, and 2 months in the third patient. Our case reports show the occurrence of reversible PLES in HCV-positive long-term HD patients treated with IFN-alpha. Physicians caring for HCV-positive long-term HD patients treated with IFN-alpha need to be particularly cautious when these patients receive simultaneously recombinant erythropoietin and when IFN-alpha therapy induces a weight loss, which indicates a reduction in dry weight.
Kamar
N
N
Nephrology, Hemodialysis and Multiorgan Transplant Unit, Laboratory of Virology, and Department of Neuroradiology, Toulouse University Hospital, Toulouse, France.
Kany
M
M
Bories
P
P
Ribes
D
D
Izopet
J
J
Durand
D
D
Rostaing
L
L
D000328:Adult; D000740:Anemia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D001927:Brain Diseases / Q000139:chemically induced / Q000209:etiology*; D015897:Comorbidity; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000150:complications / Q000453:epidemiology; D007375:Interleukin-1 / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D013577:Syndrome
D007375:Interleukin-1; D011994:Recombinant Proteins; D004921:Erythropoietin